A recent study suggests that people who discontinue new slimming jabs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Research printed in a major health publication shows that while overweight people often shed substantial amounts of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users using such drugs must be aware of the potential of quick rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment weight within about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
The team point out that people who lose weight through lifestyle changes alone usually experience a less rapid weight regain—around 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Experts propose the mode of action of the drugs accounts for the accelerated regain.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the therapy is often life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "emphasize the long-term nature of obesity," comparing it to managing diseases like diabetes.
User Accounts
Users who have discontinued the jabs report a intense return of appetite.
"I experienced a switch that goes on and you become ravenous," recalled one woman.
This difficulty is compounded if users have not developed lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while the jabs are effective agents for weight loss, they are not a permanent cure and maintained weight loss hinges on integrated lifestyle support.
